Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+gastroesophageal junction (GEJ) or gastric cancer (GC)
JOURNAL FOR IMMUNOTHERAPY OF CANCER. Bd. 7. 2019
Erscheinungsjahr: 2019
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Catenacci, Daniel (Autor)
Rosales, Minori (Autor)
Wigginton, Jon (Autor)
Chung, Hyun Cheol (Autor)
Yoon, Harry (Autor)
Shen, Lin (Autor)
Kang, Yoon-Koo (Autor)
Moehler, Markus (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
